drugset / Trial / NCT00035321

The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression

NCT00035321 ↗

Phase 3 Completed 600 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The purposes of this study are to determine: * Whether olanzapine plus fluoxetine in combination will help patients with treatment-resistant major depression. * The safety of olanzapine plus fluoxetine in combination, plus and any side effects that might be associated with the combination. * The effectiveness of olanzapine plus fluoxetine compared to olanzapine and fluoxetine alone.

Timeline

Start
2002-04
Primary completion
—
Completion
2005-07

Outcome

Mixed primary results

paper Study 1 revealed no statistically significant therapy differences in MADRS mean change PMID 17335320 ↗

paper In Study 2, olanzapine/fluoxetine combination demonstrated significantly greater MADRS improvement (-14.5) than fluoxetine (-8.6, p < .001) and olanzapine (-7.0, p < .001). PMID 17335320 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluoxetine Small molecule 50 mg Oral
Subject Olanzapine Small molecule 6 mg Oral
Subject Olanzapine Small molecule 18 mg Oral